Circle CVI announced on October 20, 2026, that it has joined EXIT-CVD, a five-year European cardiovascular research project with a €27.6 million budget. The imaging-software company will bring its expertise in AI-enabled cardiac image analysis to a consortium planning 22 clinical studies involving more than 14,000 patients, with initial enrollment scheduled for October 2026.
Key Takeaways
- Circle CVI will contribute cardiovascular imaging expertise to research on earlier diagnosis and personalized care.
- EXIT-CVD brings together 42 public and private partners across 17 countries, led by UMC Groningen and Philips.
- The €27.6 million project is co-funded by the EU’s Innovative Health Initiative and industry partners.
Table of Contents
- A five-year program spanning the cardiac care journey
- What Circle CVI brings to the consortium
- Studies will test monitoring, imaging and access
- Conclusion
A five-year program spanning the cardiac care journey
The EXIT-CVD clinical research program will investigate ways to prevent cardiovascular disease, reverse its progression or halt deterioration in advanced cases. University Medical Center Groningen and Philips lead the public-private partnership, whose first studies are scheduled to begin enrolling patients in October 2026.
The €27.6 million budget covers the consortium-wide project; it is not a disclosed payment to Circle CVI. The collaboration combines diagnostic technologies, digital monitoring and therapeutic approaches, with the aim of developing strategies that can be used across different European healthcare systems.
The program organizes its work around three intervention points: early detection, personalized risk assessment and targeted treatment, and advanced therapies intended to support recovery in later-stage disease. These are research objectives, not demonstrated outcomes from the planned studies.
| Item | Details |
|---|---|
| CARDIO-CAM | Evaluates video-based hospital monitoring of cardiorespiratory signals and clinical context. |
| LEADER-PAD | Develops and validates spectral CT approaches for early detection in asymptomatic and low-risk symptomatic patients. |
| REMODEL-HF | Tests non-invasive remote monitoring in patients recently hospitalized for heart failure. |
| GUIDANCE-PCCT | Compares photon-counting CT-guided coronary intervention with standard angiography-guided intervention. |
| NOTIFY-2 | Validates AI-driven image and ECG analysis for earlier diagnosis of left ventricular hypertrophy and underlying disease risk assessment. |
What Circle CVI brings to the consortium
Circle CVI develops software for cardiovascular image analysis, visualization and reporting. Its cvi42 platform combines cardiac magnetic resonance and CT analysis with coronary plaque quantification and tools for planning structural heart and electrophysiology procedures.
The platform’s capabilities include assessing cardiac function, blood flow, myocardial tissue characteristics and coronary artery disease. That expertise aligns with EXIT-CVD’s work on using imaging to distinguish disease risk and inform individual treatment decisions.
Circle CVI Chief Executive Erkan Akyuz said advanced cardiovascular imaging can help clinicians understand how disease may progress and where intervention could make a difference. The company’s announced role is to contribute imaging-analysis expertise; the announcement does not establish that its software has achieved the consortium’s intended clinical benefits.
Studies will test monitoring, imaging and access
The study portfolio ranges from hospital-based monitoring to remote care after heart-failure hospitalization. Selected studies illustrate how the consortium plans to evaluate different technologies at different stages of disease.
EXIT-CVD also plans to develop interventions with patients and address socioeconomic, sex- and gender-related, and digital-access gaps. A shared data platform aligned with the European Health Data Space is intended to support evaluation and wider implementation of the project’s innovations.
Conclusion
The next scheduled milestone is initial patient enrollment in October 2026. The studies will test whether the consortium’s imaging, monitoring and treatment approaches can deliver the intended improvements in cardiovascular care.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
